Terms: = Pancreatic cancer AND PAX5, Q02548, 5079, ENSG00000196092, BSAP AND Prognosis
3 results:
1. Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.
Chen D; Bao X; Zhang R; Ding Y; Zhang M; Li B; Zhang H; Li X; Tong Z; Liu L; Zhou X; Wang S; Cheng X; Zheng Y; Ruan J; Fang W; Zhao P
Br J Cancer; 2021 Sep; 125(7):994-1002. PubMed ID: 34331023
[TBL] [Abstract] [Full Text] [Related]
2. DGCR5 is activated by pax5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway.
Liu SL; Cai C; Yang ZY; Wu ZY; Wu XS; Wang XF; Dong P; Gong W
Int J Biol Sci; 2021; 17(2):498-513. PubMed ID: 33613108
[TBL] [Abstract] [Full Text] [Related]
3. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract] [Full Text] [Related]
